Janarthanan Sathananthan1, Stephanie Sellers2, Aaron M Barlow3, Viktória Stanová4, Rob Fraser5, Stefan Toggweiler6, Keith B Allen7, Adnan Chhatriwalla7, Dale J Murdoch8, Mark Hensey1, Karen Lau2, Abdullah Alkhodair1, Danny Dvir9, Anita W Asgar10, Anson Cheung1, Philipp Blanke11, Jian Ye1, Régis Rieu4, Phillippe Pibarot12, David Wood1, Jonathan Leipsic11, John G Webb13. 1. Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. 2. Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada; Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada. 3. Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada. 4. Aix-Marseille Univ, IFSTTAR, LBA UMR_T24, Marseille, France. 5. ViVitro Labs Inc., Victoria, British Columbia, Canada. 6. Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland. 7. Saint Luke's Hospital, St. Luke's Mid America Heart Institute, Kansas City, Missouri. 8. Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; University of Queensland, Brisbane, Australia. 9. University of Washington, Seattle, Washington. 10. Montreal Heart Institute, Montreal, Quebec, Canada. 11. Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada. 12. Quebec Heart & Lung Institute, Laval University, Quebec, Canada. 13. Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: johngraydonwebb@gmail.com.
Abstract
OBJECTIVES: The authors assessed the effect of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) followed by bioprosthetic valve fracture (BVF), testing different transcatheter heart valve (THV) designs in an ex vivo bench study. BACKGROUND: Bioprosthetic valve fracture can be performed to improve residual transvalvular gradients following VIV TAVR. METHODS: The authors evaluated VIV TAVR and BVF with the SAPIEN 3 (S3) (Edwards Lifesciences, Irvine, California) and ACURATE neo (Boston Scientific Corporation, Natick, Massachusetts) THVs. A 20-mm and 23-mm S3 were deployed in a 19-mm and 21-mm Mitroflow (Sorin Group USA, Arvada, Colorado), respectively. A small ACURATE neo was deployed in both sizes of Mitroflow tested. VIV TAVR samples underwent multimodality imaging, and hydrodynamic evaluation before and after BVF. RESULTS: A high implantation was required to enable full expansion of the upper crown of the ACURATE neo and allow optimal leaflet function. Marked underexpansion of the lower crown of the THV within the surgical valve was also observed. Before BVF, VIV TAVR in the 19-mm Mitroflow had high transvalvular gradients using either THV design (22.0 mm Hg S3, and 19.1 mm Hg ACURATE neo). After BVF, gradients improved and were similar for both THVs (14.2 mm Hg S3, and 13.8 mm Hg ACURATE neo). The effective orifice area increased with BVF from 1.2 to 1.6 cm2 with the S3 and from 1.4 to 1.6 cm2 with the ACURATE neo. Before BVF, VIV TAVR with the ACURATE neo in the 21-mm Mitroflow had lower gradients compared with S3 (11.3 mm Hg vs. 16 mm Hg). However, after BVF valve gradients were similar for both THVs (8.4 mm Hg ACURATE neo vs. 7.8 mm Hg S3). The effective orifice area increased from 1.5 to 2.1 cm2 with the S3 and from 1.8 to 2.2 cm2 with the ACURATE neo. CONCLUSIONS: BVF performed after VIV TAVR results in improved residual gradients. Following BVF, residual gradients were similar irrespective of THV design. Use of a small ACURATE neo for VIV TAVR in small (≤21 mm) surgical valves may be associated with challenges in achieving optimum THV position and expansion. BVF could be considered in selected clinical cases.
OBJECTIVES: The authors assessed the effect of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) followed by bioprosthetic valve fracture (BVF), testing different transcatheter heart valve (THV) designs in an ex vivo bench study. BACKGROUND: Bioprosthetic valve fracture can be performed to improve residual transvalvular gradients following VIV TAVR. METHODS: The authors evaluated VIV TAVR and BVF with the SAPIEN 3 (S3) (Edwards Lifesciences, Irvine, California) and ACURATE neo (Boston Scientific Corporation, Natick, Massachusetts) THVs. A 20-mm and 23-mm S3 were deployed in a 19-mm and 21-mm Mitroflow (Sorin Group USA, Arvada, Colorado), respectively. A small ACURATE neo was deployed in both sizes of Mitroflow tested. VIV TAVR samples underwent multimodality imaging, and hydrodynamic evaluation before and after BVF. RESULTS: A high implantation was required to enable full expansion of the upper crown of the ACURATE neo and allow optimal leaflet function. Marked underexpansion of the lower crown of the THV within the surgical valve was also observed. Before BVF, VIV TAVR in the 19-mm Mitroflow had high transvalvular gradients using either THV design (22.0 mm Hg S3, and 19.1 mm Hg ACURATE neo). After BVF, gradients improved and were similar for both THVs (14.2 mm Hg S3, and 13.8 mm Hg ACURATE neo). The effective orifice area increased with BVF from 1.2 to 1.6 cm2 with the S3 and from 1.4 to 1.6 cm2 with the ACURATE neo. Before BVF, VIV TAVR with the ACURATE neo in the 21-mm Mitroflow had lower gradients compared with S3 (11.3 mm Hg vs. 16 mm Hg). However, after BVF valve gradients were similar for both THVs (8.4 mm Hg ACURATE neo vs. 7.8 mm Hg S3). The effective orifice area increased from 1.5 to 2.1 cm2 with the S3 and from 1.8 to 2.2 cm2 with the ACURATE neo. CONCLUSIONS: BVF performed after VIV TAVR results in improved residual gradients. Following BVF, residual gradients were similar irrespective of THV design. Use of a small ACURATE neo for VIV TAVR in small (≤21 mm) surgical valves may be associated with challenges in achieving optimum THV position and expansion. BVF could be considered in selected clinical cases.
Authors: R Yazan Kherallah; Srikanth Koneru; Zvonimir Krajcer; Ourania Preventza; Kathryn G Dougherty; Melissa L McCormack; Briana T Costello; Stephanie Coulter; Neil E Strickman; Juan Carlos Plana Gomez; Ali Mortazavi; Jose G Díez; James J Livesay; Joseph S Coselli; Guilherme V Silva Journal: Ann Cardiothorac Surg Date: 2021-09
Authors: Xiling Zhang; Thomas Puehler; Derk Frank; Janarthanan Sathananthan; Stephanie Sellers; David Meier; Marcus Both; Philipp Blanke; Hatim Seoudy; Mohammed Saad; Oliver J Müller; Lars Sondergaard; Georg Lutter Journal: J Cardiovasc Dev Dis Date: 2022-07-12
Authors: Horea Feier; Andrei Grigorescu; Lucian Falnita; Oana Rachita; Marian Gaspar; Constantin T Luca Journal: J Clin Med Date: 2021-05-11 Impact factor: 4.241
Authors: Isaac Pascual; Marcel Almendárez; Rut Álvarez Velasco; Antonio Adeba; Daniel Hernández-Vaquero; Rebeca Lorca; Rocío Díaz; Alberto Alperi; Héctor Cubero-Gallego; Jose Rozado; César Morís; Pablo Avanzas Journal: Ann Transl Med Date: 2020-08